NASDAQ:CSBR Champions Oncology (CSBR) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free CSBR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.80▼$5.1350-Day Range$9.11▼$10.9652-Week Range$7.19▼$14.68Volume668 shsAverage Volume2,336 shsMarket Capitalization$69.72 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaSustainability Get Champions Oncology alerts: Email Address Champions Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside46.2% Upside$7.50 Price TargetShort InterestBearish0.93% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment1.04Based on 66 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.41 out of 5 starsMedical Sector1729th out of 5,424 stocksBiological Products, Except Diagnostic Industry202nd out of 909 stocks 3.3 Analyst's Opinion Consensus RatingChampions Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageChampions Oncology has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.93% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Champions Oncology has recently decreased by 2.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldChampions Oncology does not currently pay a dividend.Dividend GrowthChampions Oncology does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChampions Oncology has received a 71.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Champions Oncology is -0.81. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 66 news articles for Champions Oncology this week, compared to 13 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Champions Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders45.69% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Champions Oncology is -7.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Champions Oncology is -7.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChampions Oncology has a P/B Ratio of 15.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Champions Oncology Stock (NASDAQ:CSBR)Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Read More Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. CSBR Stock News HeadlinesMay 4, 2024 | msn.comFans vote with feet as Champions Cup semi-final weekend set for bumper attendanceMay 3, 2024 | msn.comChampions Cup semi-final teams: Five takeaways from the squads as Leinster ditch 6-2 split and Toulouse bench Thomas RamosMay 4, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 3, 2024 | msn.comTottenham’s Champions League hopes hit further by 2-0 loss at Chelsea in Premier LeagueMay 2, 2024 | msn.comColumbus Crew vs CF Pachuca: Date set for CONCACAF Champions Cup finalMay 2, 2024 | msn.comWith PSG crowned French champion, the race for remaining Champions League spots rumbles onMay 2, 2024 | msn.comBundesliga could have six clubs in next season's Champions LeagueMay 2, 2024 | sports.yahoo.comEverything you need to know about the new Champions League formatMay 4, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 2, 2024 | msn.comTottenham's Champions League hopes hit further by 2-0 loss at Chelsea in Premier LeagueMay 2, 2024 | msn.comTottenham suffer huge blow after Borussia Dortmund’s Champions League winMay 2, 2024 | msn.comCONCACAF Champions Cup final moved to June 1 to avoid conflict with Mexican electionsMay 2, 2024 | abcnews.go.comBillie Jean King is getting the Breakfast of Champions treatment. She'll appear on a Wheaties boxMay 2, 2024 | msn.comKylian Mbappe gets left out of PSG’s team bus after Champions League defeatMay 2, 2024 | msn.comTen Hag heaps praise on exiled Sancho after Champions League star turnMay 1, 2024 | msn.comFüllkrug fires Dortmund to 1-0 win over Mbappé's PSG in Champions League semifinal first legMay 1, 2024 | msn.comFans excited to come out for Champions Day at Churchill Downs during Derby weekMay 1, 2024 | barrons.com'Big Stage' Sancho Back To Scintillating Best In Champions League SemiMay 1, 2024 | forbes.comBorussia Dortmund Glory Would Fittingly End This Champions League FormatMay 1, 2024 | msn.comChampions Day crowd, local bets driving excitement for Derby 150May 1, 2024 | barrons.comPSG Optimistic About Champions League Chances Despite Dortmund DefeatMay 1, 2024 | msn.comPremier League misses fifth Champions League spotMay 1, 2024 | msn.comVinicius Junior joins Cristiano Ronaldo in an exclusive Champions League clubMay 1, 2024 | msn.comBorussia Dortmund vs PSG LIVE: Champions League team news, line-ups and more ahead of semi-final tonightMay 1, 2024 | msn.comList of UEFA Champions League past winners: Year-by-year resultsMay 1, 2024 | msn.comChampions Trophy: All India games could be held in LahoreMay 1, 2024 | msn.comHow to Watch Champions League: Borussia Dortmund vs Paris Saint-Germain, TV Channel, Free Live StreamSee More Headlines Receive CSBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today5/04/2024Next Earnings (Estimated)7/22/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CSBR CUSIPN/A CIK771856 Webwww.championsoncology.com Phone(201) 808-8400Fax410-369-0390Employees143Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$7.50 Low Stock Price Target$7.50 Potential Upside/Downside+46.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net Margins-19.76% Pretax Margin-19.62% Return on Equity-850.72% Return on Assets-32.62% Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick Ratio0.60 Sales & Book Value Annual Sales$53.87 million Price / Sales1.29 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book15.09Miscellaneous Outstanding Shares13,590,000Free Float7,383,000Market Cap$69.72 million OptionableOptionable Beta0.40 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesRonnie MorrisPresident Chief Executive Officer & DirectorDavid Barry MillerChief Financial OfficerKarin Abarca HeidemannVice President-Scientific OperationsMichael RitchieChief Commercial OfficerMaria ManciniVice President-PharmacologyKey CompetitorsElutiaNASDAQ:ELUTInstil BioNASDAQ:TILPrecision BioSciencesNASDAQ:DTILIkena OncologyNASDAQ:IKNAJATT AcquisitionNYSE:JATTView All CompetitorsInsiders & InstitutionsMesirow Financial Investment Management Inc.Bought 12,380 shares on 4/26/2024Ownership: 0.091%Aristides Capital LLCSold 9,800 shares on 2/13/2024Ownership: 0.087%Essex Investment Management Co. LLCSold 28,135 shares on 2/8/2024Ownership: 0.568%Daniel Newman MendelsonBought 1,000 shares on 1/12/2024Total: $6,500.00 ($6.50/share)Daniel Newman MendelsonBought 2,944 shares on 1/10/2024Total: $18,576.64 ($6.31/share)View All Insider TransactionsView All Institutional Transactions CSBR Stock Analysis - Frequently Asked Questions Should I buy or sell Champions Oncology stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CSBR shares. View CSBR analyst ratings or view top-rated stocks. What is Champions Oncology's stock price target for 2024? 2 Wall Street analysts have issued 1-year target prices for Champions Oncology's shares. Their CSBR share price targets range from $7.50 to $7.50. On average, they anticipate the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 46.2% from the stock's current price. View analysts price targets for CSBR or view top-rated stocks among Wall Street analysts. Are investors shorting Champions Oncology? Champions Oncology saw a decrease in short interest in March. As of March 31st, there was short interest totaling 58,100 shares, a decrease of 7.2% from the March 15th total of 62,600 shares. Based on an average daily trading volume, of 7,000 shares, the short-interest ratio is currently 8.3 days. Approximately 1.0% of the company's stock are sold short. View Champions Oncology's Short Interest. When is Champions Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024. View our CSBR earnings forecast. How were Champions Oncology's earnings last quarter? Champions Oncology, Inc. (NASDAQ:CSBR) announced its quarterly earnings results on Tuesday, March, 12th. The biotechnology company reported ($0.19) EPS for the quarter. The biotechnology company had revenue of $12.02 million for the quarter. Champions Oncology had a negative trailing twelve-month return on equity of 850.72% and a negative net margin of 19.76%. What is Ronnie Morris' approval rating as Champions Oncology's CEO? 8 employees have rated Champions Oncology Chief Executive Officer Ronnie Morris on Glassdoor.com. Ronnie Morris has an approval rating of 50% among the company's employees. This puts Ronnie Morris in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Champions Oncology investors own include Gilead Sciences (GILD), Intel (INTC), Cytosorbents (CTSO), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), AbbVie (ABBV), Agile Therapeutics (AGRX), CRISPR Therapeutics (CRSP) and Exelixis (EXEL). Who are Champions Oncology's major shareholders? Champions Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Mesirow Financial Investment Management Inc. (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel Newman Mendelson and Ronnie Morris. View institutional ownership trends. This page (NASDAQ:CSBR) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryThe only defense company you should be looking atBehind the MarketsThe asset beating inflation by 4xColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
